These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 4725926)

  • 61. Evidence for the action of d-lysergic acid diethylamide, mescaline and bufotenine on 5-hydroxytryptamine receptors in umbilical vasculature.
    Dyer DC
    J Pharmacol Exp Ther; 1974 Feb; 188(2):336-41. PubMed ID: 4359552
    [No Abstract]   [Full Text] [Related]  

  • 62. Potentiation of bufotenine-like syndrome induced by diethyltryptamine in reserpinized rats.
    Khazan N; Hirsch A; Sulman FG
    Electroencephalogr Clin Neurophysiol; 1967 Jun; 22(6):589. PubMed ID: 4165027
    [No Abstract]   [Full Text] [Related]  

  • 63. Synthesis and central nervous system activity of 1,2,3,4-tetrahydro-1-amino-4-phenylnaphthalenes.
    Walter LA; Chang WK; Kenney J; Douvan I
    J Med Chem; 1974 Apr; 17(4):459-63. PubMed ID: 4830546
    [No Abstract]   [Full Text] [Related]  

  • 64. Indolamine hallucinogens as MAO inhibitor agents--theoretical approach.
    Brandys Y; Yehuda S
    Int J Neurosci; 1983 Nov; 21(3-4):251-5. PubMed ID: 6671882
    [TBL] [Abstract][Full Text] [Related]  

  • 65. 2,5-Dimethoxy-4-methylamphetamine (DOM), a neuropharmacological examination.
    Wallach MB; Friedman E; Gershon S
    J Pharmacol Exp Ther; 1972 Jul; 182(1):145-54. PubMed ID: 4261221
    [No Abstract]   [Full Text] [Related]  

  • 66. On the role of serotonin in apomorphine-induced locomotor stimulation in rats.
    Grabowska M; Michaluk J
    Pharmacol Biochem Behav; 1974; 2(2):263-6. PubMed ID: 4829602
    [No Abstract]   [Full Text] [Related]  

  • 67. Hallucinogenic indoleamines: Preferential action upon presynaptic serotonin receptors.
    Aghajanian GK; Hailgler HJ
    Psychopharmacol Commun; 1975; 1(6):619-29. PubMed ID: 1063421
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interactions of 5-hydroxytryptamine and narcotic analgesics on dog intestine in vivo.
    de Oliveira LF; Sollero L
    Pharmacology; 1973; 10(5):291-7. PubMed ID: 4764535
    [No Abstract]   [Full Text] [Related]  

  • 69. Stimulus properties of phenethylamine hallucinogens and lysergic acid diethylamide: the role of 5-hydroxytryptamine.
    Winter JC
    J Pharmacol Exp Ther; 1978 Feb; 204(2):416-23. PubMed ID: 621672
    [No Abstract]   [Full Text] [Related]  

  • 70. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.
    Monte AP; Waldman SR; Marona-Lewicka D; Wainscott DB; Nelson DL; Sanders-Bush E; Nichols DE
    J Med Chem; 1997 Sep; 40(19):2997-3008. PubMed ID: 9301661
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine.
    Blair JB; Marona-Lewicka D; Kanthasamy A; Lucaites VL; Nelson DL; Nichols DE
    J Med Chem; 1999 Mar; 42(6):1106-11. PubMed ID: 10090793
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Failure of N,N-dimethyltryptamine to evoke tolerance in cats.
    Gillin JC; Cannon E; Magyar R; Schwartz M; Wyatt RJ
    Biol Psychiatry; 1973 Dec; 7(3):213-20. PubMed ID: 4519415
    [No Abstract]   [Full Text] [Related]  

  • 73. Recognition and activation mechanisms on the LSD/serotonin receptor: the molecular basis of structure activity relationships.
    Weinstein H; Green JP; Osman R; Edwards WD
    NIDA Res Monogr; 1978; (22):333-58. PubMed ID: 101884
    [No Abstract]   [Full Text] [Related]  

  • 74. Quantum chemical studies on drug actions. 3. Correlation of hallucinogenic and anti-serotonin activity of lysergic acid derivatives with quantum chemical data.
    Kumbar M; Sankar DV
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):65-100. PubMed ID: 4734018
    [No Abstract]   [Full Text] [Related]  

  • 75. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis.
    Marona-Lewicka D; Thisted RA; Nichols DE
    Psychopharmacology (Berl); 2005 Jul; 180(3):427-35. PubMed ID: 15723230
    [TBL] [Abstract][Full Text] [Related]  

  • 76. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Facilitation of discriminated leverpress avoidance learning by ribaminol.
    Erickson CK
    Life Sci I; 1972 Jan; 11(1):23-32. PubMed ID: 4653189
    [No Abstract]   [Full Text] [Related]  

  • 78. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action.
    Marona-Lewicka D; Nichols DE
    Pharmacol Biochem Behav; 2007 Oct; 87(4):453-61. PubMed ID: 17618679
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Receptors for sympathomimetic amines and 5-hydroxytryptamine in the rat aorta.
    Krishnamurty VS
    Arch Int Pharmacodyn Ther; 1971 Jan; 189(1):90-9. PubMed ID: 5130156
    [No Abstract]   [Full Text] [Related]  

  • 80. Correlation between animal and clinical findings with a psychotomimetic anticholinesterase.
    Wray SR; Cowan A
    Neuropharmacology; 1973 Apr; 12(4):397-400. PubMed ID: 4703881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.